Valirx Share Discussion Threads

[tburns] 07/9/2020 09:06

Can see 30p in the rear view mirror this afternoon. GLA

[jungmana] 07/9/2020 08:54

If you look at the trades over last one week imo should see 40p+ before the 201 results

[stockhunters] 07/9/2020 08:54

above resistance

[deanmatlazin] 07/9/2020 08:49

Cheap as chips still with compound that can treat prostate cancer. billions of pounds market

[412069] 07/9/2020 08:48

Must be by now.

[jungmana] 07/9/2020 08:47

I think institutions loading up here

[jungmana] 07/9/2020 08:46

I think institutions loading up here

[deanmatlazin] 07/9/2020 08:44

Up to 40p....hope it will go to £1 after VAL 201 result

[deanmatlazin] 07/9/2020 07:58

Prostate cancer treatment worth billions of pounds. This will rocket

[thebossman] 07/9/2020 07:35

7th September 2020

Post-period highlights

Strategy development

On 6 July 2020, the Company announced that it had launched a new strategy with the intent to expand the development pipeline with new preclinical therapeutic assets. Recognising the Company's strength in Women's Health and Oncology, ValiRx has prioritised these indications in seeking new projects for further development and possible spin-out into Special Purpose Vehicles (SPV). Such SPVs will operate as subsidiary companies and reduce risk by seeking partners to finance clinical trials. By providing intellectual, corporate and financial resources, the Company believes it can add value to early stage drug development projects and present a strong commercial package for external funding and partnering.

Project identification and screening is underway and an Advisory Board is being appointed.



Outlook

With the structural changes in the Company nearly complete, the Company intends to accelerate the strategy of risk-managed growth and build on the existing pipeline of projects to ensure progress is obtained in a resource-efficient manner.



Dr S Dilly

[nico115] 07/9/2020 07:29

Pleased with that No more fund raises Huge blockbuster drug potential Tiny market cap Multi bag potential

[jasonpugh] 07/9/2020 07:21

Well done Suzy and team

[deanmatlazin] 07/9/2020 07:18

What not to like...VAL 201 is the big one. This will propel the share price to multiple from current price.

[tburns] 07/9/2020 07:14

Seems like a solid 1/2 year report, costs rained in, losses dramatically reduced, pipeline bulging and clear strategic aim to grow from here. What is not to like. Bring on the 201 results. GLA

[shares188] 06/9/2020 18:45

Wow 100m Market cap!
That would be easily £1.50
😉
Passing 32p then it's as good
as 50p, good news straight to
£1

[jassyb55] 06/9/2020 11:18

Trying to work out/guess-estimate out the market cap of this company pre-results of VAL 201. Has to be at least 25-30 mill, share price of 43-52p.

if results are good- bingo!!

[hodhasharon] 06/9/2020 10:46

No smoke without fire, I’m backing both ponies; Val and PYC.

Stig’s research is unrivalled in terms of both depth and objectivity.

[the stigologist] 06/9/2020 09:58

osted on PYC thread some interesting things VAL shareholders might want to have a read

May or may not all be connected

1. Valirx VAL201 Phase I/II results due September
2. Physiomics have licence share of VAL201
3. Physiomics in August tweeted about VAL201
4. The BIGGEST SELLING PROSTATE CANCER DRUG is Astellas Xtandi (c.$3 Billion p.a.)
5. Physiomics signed a deal with Astellas this Summer (Astellas are Japanese and 19th Largest Pharma in World)
6. Physiomics have expertise in Cancer Modelling. Particularly Prostate Cancer. (Developing Prostate Cancer Precision Dosing Tool with UK Government finance)

(May or may not also be related ? A Japanese Pharma investigating other VAL product? Astellas or Competitor ?)


Post here :-

[the stigologist] 06/9/2020 09:57

Posted on PYC thread some interesting things VAL shareholders might want to have a read

May or may not all be connected

1. Valirx VAL201 Phase I/II results due September
2. Physiomics have licence share of VAL201
3. Physiomics in August tweeted about VAL201
4. The BIGGEST SELLING PROSTATE CANCER DRUG is Astellas Xtandi (c.$3 Billion p.a.)
5. Physiomics signed a deal with Astellas this Summer (Astellas are Japanese and 19th Largest Pharma in World)
6. Physiomics have expertise in Cancer Modelling. Particularly Prostate Cancer. (Developing Prostate Cancer Precision Dosing Tool with UK Government finance)

(May or may not also be related ? A Japanese Pharma investigating other VAL product? Astellas or Competitor ?)

Post here :-

[uknighted] 06/9/2020 09:30

jasonpugh you should not comment on posts you haven’t read. Some investors might be stupid enough to rely on your comments, many of which on this thread over time have been proven to be spurious.

[jasonpugh] 06/9/2020 09:27

Look at post timed from 14:57 hrs yesterday
Not from me.. don’t shoot the messenger..
I personally don’t think it’s authentic

[uknighted] 06/9/2020 09:22

Jasonpugh would you share with us this broker note or is it just another of your FANTASIES?